Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy

Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.

Detalles Bibliográficos
Autores principales: Al‐Katib, Ayad M., Gaith, Hussein, Sano, Dahlia, Al‐Katib, Sayf, Bonnett, Michelle, Kafri, Zyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495781/
https://www.ncbi.nlm.nih.gov/pubmed/32983498
http://dx.doi.org/10.1002/ccr3.3019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495781/
https://www.ncbi.nlm.nih.gov/pubmed/32983498
http://dx.doi.org/10.1002/ccr3.3019

Ejemplares similares